Relationships between iron dose, hospitalizations and mortality in incident haemodialysis patients: A propensity-score matched approach

Nephrology Dialysis Transplantation

Volumn 33, Issue 1, 2018, Pages 160-170

  Varas, Javier ^a   Ramos, Rosa ^a   Aljama, Pedro ^b   Perez García, Rafael ^c   Moreso, Francesc ^c   Pinedo, Miguel ^a   Ignacio Merello, Jose ^a   Stuard, Stefano ^d   Canaud, Bernard ^d   Martín Malo, Alejandro ^b  

^a AUTONOMOUS UNIVERSITY OF MADRID   (Spain)

^b HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^c HOSPITAL UNIVERSITARIO INFANTA LEONOR   (Spain)

^d FRESENIUS MEDICAL CARE   (Germany)

Author keywords

Anaemia; Haemodialysis; Hospitalization; Intravenous iron; Mortality

Indexed keywords

HEMOGLOBIN; IRON SACCHARATE; RECOMBINANT ERYTHROPOIETIN; IRON;

ADULT; AGED; ANEMIA; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG INDICATION; DRUG MEGADOSE; FEMALE; FOLLOW UP; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HOSPITALIZATION; HUMAN; INFECTION; IRON DEFICIENCY; LABORATORY TEST; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MORTALITY RISK; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROPENSITY SCORE; SURVIVAL RATE; INTRAVENOUS DRUG ADMINISTRATION; KAPLAN MEIER METHOD; MIDDLE AGED; PROCEDURES; RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA; TRENDS;

ADMINISTRATION, INTRAVENOUS; ADULT; AGED; FEMALE; HOSPITALIZATION; HUMANS; IRON; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MORTALITY; PROPENSITY SCORE; RENAL DIALYSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 85040839508     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfx209     Document Type: Article

References (53)

1. Locatelli F, De Francisco A, Deray G et al. Mortality and cardiovascular morbidity associated with haemoglobin levels: a pooled analysis of randomised controlled trials. Nephron Clin Pract 2014; 128: 323-332
2. Stauffer ME, Fan T. Prevalence of anemia in chronic kidney disease in the United States. PLoS ONE 2014; 9: 2-5
3. Macdougall IC, Bircher AJ, Eckardt K-U et al. Iron management in chronic kidney disease: conclusions from a 'Kidney Disease: Improving Global Outcomes' (KDIGO) Controversies Conference. Kidney Int 2016; 89: 28-39
4. HörlWH. Clinical aspects of iron use in the anemia of kidney disease. J Am Soc Nephrol 2007; 18: 382-393
5. Sargent JA, Acchiardo SR. Iron requirements in hemodialysis. Blood Purif 2004; 22: 112-123
6. Yang J-Y, Lee T-C, Montez-Rath ME et al. Trends in acute nonvariceal upper gastrointestinal bleeding in dialysis patients. J Am Soc Nephrol 2012; 23: 495-506
7. Wish JB. Assessing iron status: beyond serum ferritin and transferrin saturation. Clin J AmSoc Nephrol 2006; 1: 4-8
8. Tessitore N, Solero GP, Lippi G et al. The role of iron status markers in predicting response to intravenous iron in haemodialysis patients on maintenance erythropoietin. Nephrol Dial Transplant 2001; 16: 1416-1423
9. Ferrari P, Kulkarni H, Dheda S et al. Serum iron markers are inadequate for guiding iron repletion in chronic kidney disease. Clin J Am Soc Nephrol 2011; 6: 77-83
10. Ratcliffe LEK, Thomas W, Glen J et al. Diagnosis and management of iron deficiency in CKD: a summary of the NICE guideline recommendations and their rationale. Am J Kidney Dis 2016; 67: 548-558
11. Vaziri NDD. Understanding iron: promoting its safe use in patients with chronic kidney failure treated by hemodialysis. Am J Kidney Dis 2013; 61: 992-1000
12. Schiesser D. Weekly low-dose treatment with intravenous iron sucrose maintains iron status and decreases epoetin requirement in iron-replete haemodialysis patients. Nephrol Dial Transplant 2006; 21: 2841-2845
13. Rostoker G, GriuncelliM, Loridon C et al. Hemodialysis-associated hemosiderosis in the era of erythropoiesis-stimulating agents: a MRI study. Am J Med 2012; 125: 991-999
14. Rosati A, Tetta C, Merello JI et al. Cumulative iron dose and resistance to erythropoietin. J Nephrol 2015; 28: 603-613
15. Bailie GR, Larkina M, Goodkin DA et al. Data from the dialysis outcomes and practice patterns study validate an association between high intravenous iron doses and mortality. Kidney Int 2015; 87: 162-168
16. Ravani P, Palmer SC, Oliver MJ et al. Associations between hemodialysis access type and clinical outcomes: a systematic review. J Am Soc Nephrol 2013; 24: 465-473
17. Perez-Garc?a R, Palomares-Sancho I, Merello-Godino JI et al. Epidemiological study of 7316 patients on haemodialysis treated in FME clinics in Spain, using data from the EuCliDVR database: results from years 2009-2010. Nefrolog?a 2012; 32: 743-753
18. Locatelli F, Barany P, Covic A et al. Kidney disease: improving global outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement. Nephrol Dial Transplant 2013; 28: 1346-1359.
19. Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney Int 2012; 2: 279-335
20. Austin PC. A comparison of 12 algorithms for matching on the propensity score. StatMed 2014; 33: 1057-1069
21. Thoemmes F. Propensity score matching in SPSS. http://arxiv. org/abs/1201. 6385 (24May 2017, date last accessed)
22. Besarab A, Kaiser JW, Frinak S. A study of parenteral iron regimens in hemodialysis patients. Am J Kidney Dis 1999; 34: 21-28
23. Charytan C, Levin N, Al-Saloum M et al. Efficacy and safety of iron sucrose for iron deficiency in patients with dialysis-associated anemia: North American clinical trial. Am J Kidney Dis 2001; 37: 300-307
24. Fishbane S, Frei GL, Maesaka J. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis 1995; 26: 41-46
25. Schaefer RM, Schaefer L. Iron monitoring and supplementation: how do we achieve the best results? Nephrol Dial Transplant 1998; 13: 9-12
26. Singh AK, Coyne DW, Shapiro W et al. the DRIVE Study Group. Predictors of the response to treatment in anemic hemodialysis patients with high serum ferritin and low transferrin saturation. Kidney Int 2007; 71: 1163-1171
27. Bailie GR, Larkina M, Goodkin DA et al. Variation in intravenous iron use internationally and over time: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2013; 28: 2570-2579
28. Del Vecchio L, Longhi S, Locatelli F. Safety concerns about intravenous iron therapy in patients with chronic kidney disease. Clin Kidney J 2016; 9: 260-267
29. Coyne DW, Kapoian T, Suki W et al. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serumferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J AmSoc Nephrol 2007; 18: 975-984
30. Kapoian T, O'Mara NB, Singh AK et al. Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. J Am Soc Nephrol 2008; 19: 372-379
31. Rambod M, Kovesdy CP, Kalantar-Zadeh K. Combined high serum ferritin and low iron saturation in hemodialysis patients: the role of inflammation. Clin J AmSoc Nephrol 2008; 3: 1691-1701
32. Kalantar-Zadeh K. The fascinating but deceptive ferritin: to measure it or not to measure it in chronic kidney disease? Clin J AmSoc Nephrol 2006; 1: S9-S18
33. Kalantar-Zadeh K, Rodriguez RA, Humphreys MH. Association between serum ferritin and measures of inflammation, nutrition and iron in haemodialysis patients. Nephrol Dial Transplant 2004; 19: 141-149
34. Kalantar-Zadeh K, Don BR, Rodriguez RA et al. Serum ferritin is a marker of morbidity and mortality in hemodialysis patients. Am J Kidney Dis 2001; 37: 564-572
35. Park KS, Ryu GW, Jhee JH et al. Serum ferritin predicts mortality regardless of inflammatory and nutritional status in patients starting dialysis: a prospective cohort study. Blood Purif 2015; 40: 209-217
36. Kim T, Rhee CM, Streja E et al. Longitudinal trends in serum ferritin levels and associated factors in a national incident hemodialysis cohort. Nephrol Dial Transplant 2017; 32: 370-377
37. Panichi V, Rosati A, Bigazzi R et al. Anaemia and resistance to erythropoiesisstimulating agents as prognostic factors in haemodialysis patients: results from the RISCAVID study. Nephrol Dial Transplant 2011; 26: 2641-2648
38. Goldstein SL, Ikizler TA, ZappitelliMet al. Non-infected hemodialysis catheters are associated with increased inflammation compared to arteriovenous fistulas. Kidney Int 2009; 76: 1063-1069
39. Praga M, Merello JI, Palomares I et al. Type of vascular access and survival among very elderly hemodialysis patients. NephronClin Pract 2013; 124: 47-53
40. Feldman HI, Joffe M, Robinson B et al. Administration of parenteral iron and mortality among hemodialysis patients. J AmSocNephrol 2004; 15: 1623-1632
41. Kalantar-Zadeh K, Regidor DL,McAllister CJ et al. Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol 2005; 16: 3070-3080
42. Feldman HI, Santanna J, GuoWet al. Iron administration and clinical outcomes in hemodialysis patients. J Am Soc Nephrol 2002; 13: 734-744
43. Brookhart MA, Freburger JK, Ellis AR et al. Infection risk with bolus versus maintenance iron supplementation in hemodialysis patients. J Am Soc Nephrol 2013; 24: 1151-1158
44. Kshirsagar AV, Freburger JK, Ellis AR et al. Intravenous iron supplementation practices and short-term risk of cardiovascular events in hemodialysis patients. PLoS ONE 2013; 8: e78930
45. Kuo K-L, Hung S-C, Lin Y-P et al. Intravenous ferric chloride hexahydrate supplementation induced endothelial dysfunction and increased cardiovascular risk among hemodialysis patients. PLoS ONE 2012; 7: e50295
46. Ishida JH, Johansen KL. Iron and infection in hemodialysis patients. Semin Dial 2008; 27: 26-36
47. Diskin CJ, Stokes TJ, Dansby LM et al. Is systemic heparin a risk factor for catheter-related sepsis in dialysis patients? An evaluation of various biofilm and traditional risk factors. Nephron Clin Pract 2007; 107: c128-c132
48. Kuragano T,Matsumura O,Matsuda A et al. Association between hemoglobin variability, serum ferritin levels, and adverse events/mortality in maintenance hemodialysis patients. Kidney Int 2014; 86: 845-854
49. Zitt E, Sturm G, Kronenberg F et al. Iron supplementation and mortality in incident dialysis patients: an observational study. PLoS One 2014; 9: 1-19
50. Miskulin DC, Tangri N, Bandeen-Roche K et al. Intravenous iron exposure and mortality in patients on hemodialysis. Clin J Am Soc Nephrol 2014; 9: 1930-1939
51. Tangri N, Miskulin DC, Zhou J et al. Effect of intravenous iron use on hospitalizations in patients undergoing hemodialysis: a comparative effectiveness analysis from the DEcIDE-ESRD study. Nephrol Dial Transplant 2015; 30: 667-675
52. Martin-Malo A, Merino A, Carracedo J et al. Effects of intravenous iron on mononuclear cells during the haemodialysis session. Nephrol Dial Transplant 2012; 27: 2465-2471
53. EU Clinical Trials Register. The PIVOTAL Study: https://www. clinicaltrials register. eu/ctr-search/trial/2013-002267-25/GB (24 May 2017, date last accessed)